Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-03T02:36:15.375Z Has data issue: false hasContentIssue false

Nitrazepam (Mogadon) as a Sleep-Inducing Agent

An analysis based on a double-blind comparison with phenobarbitone

Published online by Cambridge University Press:  29 January 2018

Terje Andersen
Affiliation:
University Psychiatric Clinic, Vinderen, Oslo 3, Norway
Odd Lingjærde
Affiliation:
University Psychiatric Clinic, Vinderen, Oslo 3, Norway

Extract

Nitrazepam is a benzodiazepine closely related to diazepam and chlordiazepoxide. It has been marketed as a sleep-inducing drug, and as such has proved to have an overall effectiveness comparable to that of the barbiturates and related drugs (3, 4, 5, 6, 8, 12).

Type
Research Article
Copyright
Copyright © Royal College of Psychiatrists, 1969 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Akre, T., and Lingjærde, O. (1960). “Propiomazin (Propavan)—et nytt hypnotikum av fenothiazingruppen.” T. norske Lageforen., 79, 1108–13.Google Scholar
2 Armitage, P. (1955). “Tests for linear trends in proportions and frequencies.” Biometrics, 11, 375–86.CrossRefGoogle Scholar
3 Davies, C., and Levine, S. (1967). “A controlled comparison of nitrazepam (Mogadon) with sodium amylobarbitone as a sleep-inducing agent.” Brit. J. Psychiat., 113, 1005–8.CrossRefGoogle Scholar
4 Flach, G. (1964). “En ny clopoxidum analog (Ro 4·5360) som sovemiddel sammenlignet med allypropymal.” Nord. Med., 72, 1071–5.Google Scholar
5 Freuchen, I., and Östergaard, J. (1966).“Mogadon. Et nyt hypnoticum.” Ugeskr. Lager, 128, 142–3.Google Scholar
6 Haider, I. (1968a). “A double-blind controlled trial of a non-barbiturate hypnotic, nitrazepam.” Brit. J. Psychiat., 114, 337–43.CrossRefGoogle Scholar
7 Haider, I. (1968b). “Patterns of insomnia in depressive illness: a subjective evaluation.” Ibid., 114, 1127–32.Google Scholar
8 Harrer, G. (1965). “Zur Methodik der klinischen Prüfung von Schlafmitteln. Erfahrungen mit 1, 3-Dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-on.” Arzneimittelforsch., 15, 1152–4.Google Scholar
9 Muños, J. G., and Levitas, A. (1965). “Über den durch Medikamente und Placebo hervorgerufenen Schlaf.” Ibid., 15, 1118–25.Google Scholar
10 Randall, L. O., Schallek, W., Scheckel, C., Bagdon, R. E., and Rieder, J. (1965). “Zur Pharmakologie von Mogadon, einem Schlafmittel mit neuartigem Wirkungsmechanismus.” Schw. med. Wschr., 95, 334–7.Google Scholar
11 Soulairac, A., Cahn, J., Gottesmann, C., and Alano, J. (1965). “Neuropharmacological aspects of the action of hypnogenic substances on the central nervous system.” In: Sleep Mechanisms (eds. Akert, , Bally, and Schadé, ). Amsterdam.Google Scholar
12 Tetreault, L., Richer, P., Juretic, A., and Bordeleau, J. M. (1966). “Études des propriétés hypnotiques d'une nouvelle benzodiazépine, le Mogadon.” Union mid. Canada, 95, 45–9.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.